OAC
BBIO icon

OMERS Administration Corp’s BridgeBio Pharma BBIO Stock Holding History

OMERS Administration Corp’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,200
Closed -$307K – 1032
2024
Q4 		$307K Hold
11,200
– – ﹤0.01% 816
2024
Q3 		$285K Hold
11,200
– – ﹤0.01% 751
2024
Q2 		$284K Buy
+11,200
New +$306K ﹤0.01% 808

Other funds holding BBIO

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

OMERS Administration Corp's BBIO Position: Q1 2025 in Review

OMERS Administration Corp sold out of BridgeBio Pharma (BBIO) in Q1 2025, closing a stake of 11,200 shares — an estimated $307K sold.

OMERS Administration Corp first reported a position in BBIO in Q2 2024 and held it in 3 quarters. The position peaked at $307K in Q4 2024. 304 funds tracked by Wall St. Rank hold BBIO as of Q1 2025.

  • OMERS Administration Corp reported no remaining BridgeBio Pharma position as of Q1 2025 after selling out during the quarter.
  • OMERS Administration Corp sold 11,200 BridgeBio Pharma shares in Q1 2025, an estimated $307K.
  • OMERS Administration Corp first reported a position in BridgeBio Pharma in Q2 2024 and held it in 3 quarters.
  • OMERS Administration Corp's BridgeBio Pharma position peaked at $307K in Q4 2024.
  • 304 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2025.

Based on OMERS Administration Corp's 13F filing for Q1 2025, filed 14 May 2025.